Fig. 8: The FPRs antagonist could inhibit the chemotaxis of SCIMP to neutrophils in vivo.

a The schematic workflow shows that pretreatment with FPRs antagonist (CsH, 50 μg per mouse) for 1 h can inhibit the chemotaxis of bronchus-perfused murine SCIMP^N (50 μg per mouse), exogenous murine SCIMP^exo (10 mg per mouse), and endogenous murine exosomes (10 mg per mouse) to neutrophils in the pulmonary situ. b, e The chemotaxis activity of murine SCIMP^exo (10 mg per mouse) from the supernatant of SCIMP-overexpressing CHO cells and the control exosomes (from the supernatant of empty vector transfected CHO cells, 10 mg per mouse) to neutrophils or FPRs⁺ neutrophils in the lung of C57 mice was assessed with or without pretreatment of FPRs antagonist using flow cytometry (n = 6 in each group). c, f The chemotaxis activity of the murine SCIMP^N (50 μg in 50 μL per mouse) and the vehicle (PBS, 50 μL per mouse) to neutrophils or FPRs⁺ neutrophils in the lung of C57 mice with or without pretreatment of FPRs antagonist was measured by flow cytometry (n = 9 in each group). d, g The chemotaxis activity of the ultracentrifuge purified endogenous exosomes released by WT or Scimp^-/- BMDMs to neutrophils or FPRs⁺ neutrophils in the lung of C57 mice with or without pretreatment with FPRs antagonist was measured by flow cytometry (n = 5 in each group). The raw data is available in the “Source Data”.